1. Home
  2. News
  3. Clinuvel Pharmaceuticals Limited
  4. SCENESSE provides photoprotection in variegate porphyria
More Clinuvel Pharmaceuticals Limited news
Clinuvel Pharmaceuticals LimitedASX: CUV

SCENESSE provides photoprotection in variegate porphyria

Mar 3, 2024 at 11:12 PM EST · Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · Mar 3, 2024 at 11:12 PM EST · 4 pages · English

On 6ix: 6ix.com/news/scenesse-provides-photoprotection-in-variegate-porphyria

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27↗

Clinuvel Pharmaceuticals Limited on 6ix

Earlier from Clinuvel Pharmaceuticals

  • CUV Appendix 4D Half Year ReportFeb 21, 2024
  • Appendix 4E and Annual Report to Shareholders 2023Aug 29, 2023
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 30, 2023
  • Quarterly Activities/Appendix 4C Cash Flow Report Re-issuedOct 30, 2022
  • S&P DJI Announces September 2022 Quarterly RebalanceSep 2, 2022

Later from Clinuvel Pharmaceuticals

  • New case of SCENESSE efficacy in vitiligo presented at AADMar 10, 2024
  • CLINUVEL initiates on market share buy-back programMar 14, 2024
  • afamelanotide in fair-skinned Parkinsons patientsJun 17, 2024
  • CLINUVEL extends Managing Director Employment AgreementJun 28, 2024
  • Afamelanotide Assists DNA Repair Response Following UVRJul 5, 2024
All Clinuvel Pharmaceuticals news releases↗

Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.

Follow Clinuvel Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer